Handelsbanken Fonder Ab Chemo Centryx, Inc. Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 27, 2022	BUY	$22.17 - $51.8 $155,190 - $362,600	7,000 New	7,000 $362,000
Q1 2022 May 11, 2022	SELL	$22.22 - $39.12 $268,862 - $473,351	-12,100 Closed	0 $0
Q2 2021 Aug 03, 2021	BUY	$9.59 - $50.88 $4,795 - $25,440	500 Added 4.31%	12,100 $162,000
Q4 2020 Feb 11, 2021	BUY	$47.25 - $65.16 $189,000 - $260,640	4,000 Added 52.63%	11,600 $718,000
Q2 2020 Aug 13, 2020	BUY	$38.58 - $65.07 $293,208 - $494,531	7,600 New	7,600 $437,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.